About Jürgen Bulitta
Jürgen B. Bulitta, Ph.D., has joined the Center for Pharmacometrics and Systems Pharmacology (CPSP) in the Department of Pharmaceutics at the UF College of Pharmacy as an Associate Professor in July 2015. He is supported by the University of Florida’s preeminence program in Drug Discovery and Development. His laboratory is located at the Lake Nona campus where Dr. Bulitta established an internationally-recognized research program in translational antimicrobial pharmacology across the UF Colleges of Pharmacy and Medicine. Prior to joining UF, he worked at Monash University in Australia.
His group uses latest pharmacometrics methodology and dynamic in vitro infection models to develop systems pharmacology models that translate mechanistic research insights into innovative, clinically relevant dosage regimens. To date, he has significantly contributed to the translational development of beta-lactam antibiotics, beta-lactam / beta-lactamase inhibitor and beta-lactam / aminoglycoside combinations, polymyxins, tedizolid (FDA approved in 2014), and fusidic acid (in Phase III). Dr. Bulitta has been / is funded by 19 peer-reviewed grants ($19M) from the NIAID / NIH, FDA, State of Florida, and the Australian equivalents of NIH and NSF and by 30 collaborative projects ($3M) with the pharmaceutical industry. Dr. Bulitta published 115 peer-reviewed papers and contributed to over 95 phase I-IV clinical trials. He is the creator and developer of the SADAPT-TRAN facilitator package to develop systems pharmacology models in the S-ADAPT population modeling software package. He received the Giorgio Segré Prize 2010 for distinct contributions in the field of pharmacokinetics and pharmacodynamics by the European Federation for Pharmaceutical Sciences (EUFEPS) and the 2012 ASCEPT Denis Wade Johnson & Johnson New Investigators Award.
Honors & Awards
Dr. Bulitta’s research focuses on multidrug-resistant bacterial ‘superbugs’ which present one of the three most serious threats to human health. His research goals are to develop and rationally optimize novel antibiotic combination dosing strategies and to discover and develop new antibiotics based on mechanistic biological insights which his group generated. Dr. Bulitta’s research focuses on Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. His group is systematically identifying unique penicillin-binding protein (PBP) receptor occupancy patterns using double beta-lactam antibiotic combinations to synergistically kill these ‘superbugs’. Moreover, Dr. Bulitta is developing novel strategies to eradicate non-replicating bacterial persisters via available antibiotics and has pioneered the field of mechanism-based and Quantitative and Systems Pharmacology modeling of antibiotics. Dr. Bulitta’s group leverages latest dynamic in vitro infection models, biochemical and molecular studies, LC-MS/MS bioanalysis, as well as latest pharmacometrics methodology to develop and rationally optimize efficacious antibiotic combinations. His highly collaborative research involves an international network of academic, clinical and industry scientists. Dr. Bulitta is collaborating with experts in animal infection models, antibiotic drug development, bacterial resistance mechanisms and genetics, transcriptomics, proteomics, metabolomics, lipidomics, medicinal chemistry, flow cytometry, advanced imaging techniques, and clinical infectious diseases.
- Acinetobacter baumannii
- Beta-lactamase inhibitors
- Eradication of non-replicating bacterial persisters
- Escherichia coli
- Klebsiella pneumoniae
- Mechanism-based mathematical modeling
- Mechanisms of antibiotic action and synergy
- Multidrug-resistant bacterial ‘superbugs’ and their resistance mechanisms
- Omics techniques and single cell analyses
- Penicillin-binding protein (PBP) occupancy patterns
- Population pharmacokinetics
- Pseudomonas aeruginosa
- Quantitative and Systems Pharmacology modeling
- Rationally optimizing anti-infective combination dosing strategies
- Staphylococcus aureus
- Translational drug development